Evidence map›Paper›PMID 30787364›Full record

ArticleScientific reports2019

Genetic characterization of thymoma.

Lei Yu, Ji Ke, Xin Du, Zhen Yu, Di Gao

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Evolutionary Restructuring and Systematic Review of theJournal of developmental biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Clinical features of thymoma with and without myasthenia gravis.Pakistan journal of medical sciences · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive Review.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Thymoma: An Overview.Diagnostics (Basel, Switzerland) · 2023
    Review
  14. Article
  15. Thymic Epithelial Tumors: An Evolving Field.Life (Basel, Switzerland) · 2023
    Review
  16. Prostate Cancer Secretome and Membrane Proteome fromInternational journal of molecular sciences · 2022
    Article
  17. Article
  18. TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study.Asian Pacific journal of cancer prevention : APJCP · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lei YuDepartment of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China. yulei1118@sohu.com.
Ji KeDepartment of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Xin DuDepartment of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Zhen YuDepartment of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Di GaoDepartment of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Tongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymoma represents the most common anterior mediastinal compartment neoplasm, originating from the epithelial cell population in the thymus. Various histological types of thymoma feature different clinical characteristics. Furthermore, thymoma is frequently associated with autoimmune disorders, esp. myasthenia gravis (MG). However, the underlying molecular tumourigenesis of thymoma remains largely unknown. The goal of our current study is to demonstrate the underlying genetic abberations in thymoma, so as to understand the possible cause of MG in thymoma patients. By using CapitalBio mRNA microarray analysis, we analyzed 31 cases of thymoma including 5 cases of type AB thymoma, 6 B1-type cases, 12 B2-type cases, 5 B2B3-type cases and 3 type-B3 cases. 6 cases of thymoma were not associated with myasthenia gravis, while 25 cases were with myasthenia gravis. By comparisons between thymoma and the paratumoral tissues, differentially expressed genes were identified preliminarily. Among them, 292 genes increased more than 2-fold, 2 genes more than 5-fold. On the other hand, 596 genes were decreased more than 2-fold, 6 genes more than 20-fold. Interestingly, among these genes upregulated more than 2-fold, 6 driver genes (FANCI, NCAPD3, NCAPG, OXCT1, EPHA1 and MCM2) were formerly reported as driver oncogenes. This microarray results were further confirmed through real-time PCR. 8 most dysregulated genes were verified: E2F2, EPHA1, CCL25 and MCM2 were upregulated; and IL6, FABP4, CD36 and MYOC were downregulated. Supervised clustering heat map analysis of 2-fold upregulated and 2-fold downregulated genes revealed 6 distinct clusters. Strikingly, we found that cluster 1 was composed of two type-B2 thymoma; and cluster 6 was three type-B2/B3 thymoma. KEGG database analysis revealed possible genetic mechanisms of thymoma and functional process. We further compared gene expression pattern between thymoma with and without MG, and found 5 genes were upregulated more than 2-fold, more than 30 genes were downregulated more than 2-fold. KEGG analysis revealed 2 important signaling pathways with more than 2-fold upregulated genes (TGF- beta signaling pathway and HTLV-I signaling pathway) as differially functioning between MG positive and negative thymomas. Real-time PCR analysis confirmed that CCL25 was upregulated; and MYC, GADD45B, TNFRSF12 downregulated in thymoma with MG. Our study thus provided important genetic information on thymoma. It shed light on the molecular bases for analyzing the functional process of thymoma and finding potential biomarkers for pathological categorizing and treatment. Our work may provide important clues in understanding possible causes of MG in thymoma patients.

Indexed as

AdultAgedBiomarkersCluster AnalysisEpithelial CellsFemaleHumansMaleMicroarray AnalysisMiddle AgedMyasthenia GravisRNA, MessengerThymomaThymus GlandThymus NeoplasmsBiomarkersRNA, Messenger

Identifiers

PMID30787364
PMCPMC6382868
OpenAlexW2916822672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.